AnalyzeDirect Xing Wei de Natale et al. Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-refractory KRAS G12C-mutant NSCLC for Immune Checkpoint Blockade Cancer Discovery.
Publication Date
February 11, 2026
How Analyze was Used
“Serial lung images were reconstructed, and tumor volumes were subsequently analyzed using Analyze 14.0 (AnalyzeDirect). Randomization was performed when at least two tumor nodules of 1mm3 each were detected by CT scan (24 days post-tumor inoculation).”
Keywords
KRAS, RAS(ON) inhibitors, Combination therapy, Immune checkpoint blockade, Immune evasion, Non-small cell lung cancer
Author Affiliation(s)
Revolution Medicines, Redwood City, California, USA
